Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.74 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3176325 | 0.85 | CES2 (1.00) | CES2SRD5A2MAPTLMNANPSR1 | |
| SCHEMBL1237189 | 0.85 | SRD5A2 (0.79) | CES2SRD5A2MAPTLMNANPSR1 | |
| SCHEMBL4086253 | 0.85 | CES2 (0.69) | CES2SRD5A2MAPTLMNANPSR1 | |
| SCHEMBL4854791 | 0.83 | CES2 (0.74) | CES2SRD5A2MAPTLMNANPSR1 | |
| SCHEMBL40186 | 0.83 | SRD5A2 (0.77) | CES2SRD5A2MAPTLMNANPSR1 | |
| SCHEMBL3816062 | 0.83 | CES2 (0.74) | CES2SRD5A2MAPTLMNANPSR1 | |
| SCHEMBL29433907 | 0.83 | SRD5A2 (0.77) | CES2SRD5A2MAPTLMNANPSR1 | |
| SCHEMBL5825944 | 0.82 | L3MBTL1 (0.55) | CES2HPGDALDH1A1 | |
| SCHEMBL39834 | 0.82 | CES2 (0.71) | CES2SRD5A2MAPTLMNANPSR1 | |
| SCHEMBL10424320 | 0.82 | CES2 (0.71) | CES2SRD5A2MAPTLMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111662275-A | Benzenesulfonamide IDH mutant inhibitor, preparation method and application thereof | 中国药科大学 | 2020-09-15 | — | — | CN | claimed |
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | AXYS PHARMACEUTICALS, INC. (US) | 2006-03-16 | — | — | US | claimed |
| EP-1472216-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | Axys Pharmaceuticals (US) | 2004-11-03 | — | — | EP | claimed |
| WO-2003066579-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARMACEUTICALS (US) | 2003-08-14 | — | — | WO | claimed |
| EP-0973767-A1 | INDAZOLES OF CYCLIC UREAS USEFUL AS HIV PROTEASE INHIBITORS | Dupont Pharmaceuticals Company (US) | 2000-01-26 | — | — | EP | claimed |
| US-5985867-A | TREATING HIV INFECTION | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-11-16 | — | — | US | claimed |
| WO-1998043969-A1 | INDAZOLES OF CYCLIC UREAS USEFUL AS HIV PROTEASE INHIBITORS | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-10-08 | — | — | WO | claimed |
| CN-111662275-B | Benzenesulfonamide IDH mutant inhibitor, preparation method and application thereof | 中国药科大学 | 2023-08-22 | — | — | CN | disclosed |
| CN-111662275-A | Benzenesulfonamide IDH mutant inhibitor, preparation method and application thereof | 中国药科大学 | 2020-09-15 | — | — | CN | disclosed |
| US-8247602-B2 | Antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120016029-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-01-19 | — | — | US | disclosed |
| US-8071807-B2 | Antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2011-12-06 | — | — | US | disclosed |
| US-20110144160-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| EP-0557877-B1 | Soluble salts of 4-amino-2-(4,4-dimethyl-imidazolidin-2-on-1-yl)-pyrimidin-5-carboxylic acid N-methyl-N-(3-trifluoromethyl-phenyl)-amide, process for their preparation, their use as medicine and initial products | HOECHST AG (DE) | 1997-09-24 | — | — | EP | disclosed |
| EP-0782164-A1 | Plasma display filter | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1997-07-02 | — | — | EP | disclosed |
| EP-0557879-B1 | 4-amino-2-ureido-5-pyrimidincarboxamide, process for their preparation, medicines containing those compounds and their use | HOECHST AG (DE) | 1997-01-08 | — | — | EP | disclosed |
| US-5571816-A | TREATMENT OF LIPID METABOLISM DISORDERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-11-05 | — | — | US | disclosed |
| EP-0557879-A1 | 4-amino-2-ureido-5-pyrimidincarboxamide, process for their preparation, medicines containing those compounds and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-09-01 | — | — | EP | disclosed |
| EP-0557877-A1 | Soluble salts of 4-amino-2-(4,4-dimethyl-imidazolidin-2-on-1-yl)-pyrimidin-5-carboxylic acid N-methyl-N-(3-trifluoromethyl-phenyl)-amide, process for their preparation, their use as medicine and initial products | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-09-01 | — | — | EP | disclosed |
| US-4225493-A | FOR POLYAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1980-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016029-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | CES2 3083/4885SRD5A2 510/4885MAPT 4847/4885 |
| US-20110144160-A1 | Antagonists of Prostaglandin D2 Receptors | PTGDR, PTGDR2, PTGER2 | CES2 3083/4885SRD5A2 510/4885MAPT 4847/4885 |
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | HDAC1, HDAC2, HDAC11 | CES2 718/4885SRD5A2 1685/4885MAPT 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.